1887

Chapter 8.1 : Introduction and General Considerations

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Introduction and General Considerations, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap8.1-1.gif /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap8.1-2.gif

Abstract:

Fungi are significant, sometimes overlooked, human pathogens. Infections range in severity from merely cosmetic to life threatening. Over the past two decades, in particular, the spectrum of agents responsible for infection has altered in response to changes in the susceptible population, notably, increases in immunocompromised subjects and greater use of antifungal agents. Fortunately, awareness of the role of opportunistic fungi in disease is growing, but with that awareness the clinical laboratory must be prepared to identify a range of fungal species. In addition, new antifungal agents less toxic than amphotericin B and variously administered have increased the requirement to identify potential pathogens to the species level. (It is no longer acceptable in most situations to report a yeast that does not produce germ tubes as “yeast, not ”) While amphotericin B is effective against many invasive fungal pathogens, newer drugs with a narrower spectrum of efficacy are available (e.g., the echinocandins). Resistance to these drugs is sometimes a species characteristic and may also be isolate dependent for other species. This section brings together the contributions of well-respected mycologists, whose expertise should help laboratories become more adept at identifying fungi, recognizing the significance of an isolated organism, and performing susceptibility testing.

Citation: Leber A. 2016. Introduction and General Considerations, p 8.1.1-8.1.2. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch8.1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818814.chap8.1
1. Gams W, Humber RA, Jaklitsch W, Kirschner R, Stadler M. 2012. Minimizing the chaos following the loss of Article 59: suggestions for a discussion. Mycotaxon 119:495507.
2. Gams W, Jaklitsch W, others. 2011. Fungal nomenclature 3. A critical response to the “Amsterdam Declaration”. Mycotaxon 116: 112.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error